1.Meningococcus Group A Immunoglobulin Therapy for Meningococcal Infection
Chinese Journal of Blood Transfusion 1988;0(02):-
The effect of an specific immunoglo- bulin to meningococcus group A was tes- ted in rabbits infected with meningococcus group A and yielded satifactory results All the 10 rabbits in the treated group appeared normal, while 5 of the 12 rabbits in the control group developed toxic symptom and DIC, and 2 died finnally. The immunoglobulin was then appli- ed clinically to 4 children with meningo- coccal meningitis. Three of them recove- red. Unfavorable outcome was found in the fourth patient, in whom meningococ- cus group B was isolated from his blood and CSF. Since meningococcus group A continues to be the predominant pathogen in our country, the above-mentioned study provides strong support for the adminis- tration of specific immunoglobulin to chil- dren with meningococcal meningitis.
2.A sensitive and convenient enzyme-linked immunosorbent assay method in serum MG7 antigen detection in gastric cancer
Bin JIN ; Xin WANG ; Yan JIN ; Zheng CHEN ; Kaichun WU ; Daiming FAN
Chinese Journal of Digestion 2016;36(3):188-191
Objective To explore a highly sensitive and highly specific method to detect the serum MG7 antigen (Ag) level for early gastric cancer diagnosis.Methods The serum MG7-Ag level was detected by enzyme-linked immunosorbent assay (ELISA) method in 116 preoperative gastric cancer patients,63 postoperative gastric cancer patients,41 patients with precancerous lesion,37 patients with precancerous diseases,50 healthy individuals and 281 patients with other cancers.Meanwhile,the expression of MG7-Ag was also examined with immunohistochemistry in patients with gastric cancer or precancerous lesion.Chi-square test was used for comparing positive rates of the two detection methods.Results The positive rate of MG7-Ag determined by ELISA was 83.6%(97/116) of preoperative gastric cancer patients,45.2%(28/62) of lung cancer patients,45.5%(20/44) of rectal cancer patients,17.6% (12/68) of colonic cancer patients,14.2% (6/42) of breast cancer patients,47.6% (30/63) of postoperative gastric cancer patients,19.5 % (8/4 1) of patients with precancerous lesions,5.4 % (2/37) of patients with precancerous diseases and 0 of healthy individuals.The sensitivity of ELISA (83.6 %) was similar with that of immunohistochemistry (94.0%)(P>0.05).However,the false positive rate of ELISA (12.8 %) was lower than that of immunohistochemistry (51.3 %) (x2 =26.491,P<0.01).There was statistically significant difference in MG7 Ag expression in gastric cancer with different clinical stages (x2=15.564,P<0.01).Conclusion This ELISA method might be a non-invasive screening method for population with high risk of gastric cancer.
3.The cytotoxic effects of Helicobacter pylori ghosts loaded with adriamyein in gastric cancer cell line
Hanbing NING ; Yongquan SHI ; Yanhong WANG ; Lianfeng ZHANG ; Kaichun WU ; Daiming FAN
Chinese Journal of Digestion 2011;31(8):527-530
Objective To synthesize H.pylori bacterial ghosts (BG) and loaded with adriamycin.The cytotoxic effects in gastric cancer cell line were also observed.MethodsThe lysis plasmid was introduced into H.pylori by bacterial conjugation. H.pylori BG were produced by inducing H.pylori lysis at 42 ℃.After suspension and centrifuge, H.pylori BG were loaded with adriamycin.The adriamycin loading quantity was measured with spectrophotometry.The cytotoxic effects of H.pylori BG-adriamycin in gastric cancer cell line SGC7901 were evaluated with MTT assay.ResultsH.pylori BG were successfully synthesized and loaded with adriamycin.The loading quantity of adriamycin was 70.4 μg/mg.H.pylori BG were seen to be adsorbed and internalized by gastric cancer cells under confocal microscope, which distributed on the surface or cytoplasmic of SGC7901 cell line. Carried Adriamycin was delivered into gastric cancer cell line and mainly accumulated in the nucleus.IC50 of SGC7901 to H.pylori BG-adriamycin was 0.32 ± 0.15 by MTT assay, which was significantly lower than that to free adriamycin (0.44 ±0.15, P<0.05).Conclusions The proliferation of gastric cancer cells were effectively inhibited by H.pylori BG-adriamycin.H.pylori BG are expected to be ideal carrier for anti-gastric cancer medicine.
4.Observation on long-term effects of percutaneous transluminal angioplasty in treating Budd-Chiari syndrome
Guohong HAN ; Chuangye HE ; Changjiang LIU ; Zhanxin YIN ; Jianhong WANG ; Xingshun QI ; Kaichun WU ; Ke XU ; Daiming FAN
Chinese Journal of Digestion 2010;30(10):725-728
Objective To evaluate the safety and efficacy of percutaneous transluminal angioplasty (PTA) in treating Budd-Chiari syndrome (BCS) and to analyze the long-term follow-up results. Methods From October 1998 to May 2008,98 BCS patients (inferior vena cava obstruction,n = 34 ; hepatic vein obstruction, n = 22; combined obstruction, n = 42) who accepted PTA treatment successfully were investigated. The changes of clinical manifestations and liver function post-operation were observed; the long term survival rate was evaluated. Results Only two patients were complicated with transhepatic puncture tract bleeding, the prognosis was good after emergency operation. Sixty patients presented with low extremities edema, which was fully subsided after PTA.Of eighty-eight ascites patients, ascites disappeared in eighty patients after operation, and in the other eight patients combined with oral diuretic treatment post-operation. The median Rotterdam prognostic score of one month post-operation and the last follow-up time point was 0. 11 and 0. 09, significantly lowered than pre-operation (1.12). The difference was statistical significance (P=0. 000). At 1, 3, 5 years postoperative, the cumulative vessel patency rates were 96%, 94% and 94% respectively, and the cumulative survival rates were 94%, 91% and 87%. Conclusions Treating BCS with PTA has a high success rate, a good safety and a long-term survival rate.
5.Clinical study on transjugular intrahepatic portosystemic shunt in treatment of portal hypertension of patients with hepatocellular carcinoma
Hao LI ; Guohong HAN ; Zhanxin YIN ; Jianhong WANG ; Shanhong TANG ; Xingshun QI ; Jie LIU ; Jielai XIA ; Kaichun WU ; Daiming FAN
Chinese Journal of Digestion 2010;30(5):293-295
Objective To evaluate the therapeutic efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) for the treatment of portal hypertension of patients with hepatocellular carcinoma.Methods Ninety-five portal hypertension patients with hepatic carcinoma were enrolled.TIPS was performed in 63 patients and the other 32 patients received support medical care.The data referred to survival time of the 95 patients after treatment was collected by follow-up visit.The informations about success rate of TIPS,hepatic encephalopathy,rebleeding and causes of death were assessed.The Kaplan-Meier method was used to compare the survival time between two groups.The association of survival time with Child-Pugh classification and model for end-stage liver disease (MELD) score was analyzed.Results The success rate of TIPS was 97.8% with reduction of mean portal vein pressure of 13.6 cmH2O(1 cmH2O=0.098 kPa).The incidence of hepatic encephalopathy was 20.6% and rebleeding was 26.3% six months after TIPS treatment.Fifty-six patients treated with TIPS died at the end of follow-up.Twelve of which were died of variceal bleeding complicated with portal hypertension.The median survival time of TIPS group (3.67 months) was significantly longer than that of control group (1 month). Moreover, the median survival time in patients with low MELD score (≤13) was significantly longer than that in those with high MELD seore (>13, x2=4.71,P=0.03). Whereas the median survival time was decreasing from Child-Pugh A to C(x2=15.6,P=0.00). Conclusions TIPS is one of effective and safe therapeutic methods to control portal hypertension. However, liver function is an important factor for selcetion of TIPS.
6.Treatment of Budd-Chiari syndrome by hepatic vein occlusion and stent replacement
Zhanxin YIN ; Guohong HAN ; Jianhong WANG ; Chuangye HE ; Xiangjie MENG ; Anhua SUN ; Jie DING ; Kaichun WU ; Daiming FAN
Chinese Journal of Digestion 2008;28(3):157-159
Objective To evaluate the effect of hepatic vein occlusion and stent replacement in treatment for Budd-Chiari syndrome(BCS).Methods Forty three patients with BCS were underwent percutanous puncture,radiography,transjugular angioplasty,balloon dilation and stent placement for hepatic vein under Doppller ultrasounographic guidance from July 2001 to September 2006. Results Technical success was 100%with no complications.The medium vein pressure was reduced from 32.5 tO 20 cm H2O(1 cm H2O-0.098 kPa)after stents replacement(P<0.01).The hepatic vein angioplasty revealed that all stents were patent and branches were disappeared.The symptoms in 38 patients were disappeared immediately,and improved in 5 patients.All patients were followed up of 32 months(ranged 1-62).Except one patient died of severe gastric bleeding,the 42 patients were survived with symptoms free.Conclusion Hepatic vein occlusion and stent replacement are safe and effective in treatment of BCS.
7.Inhibitory effects of synthetic PⅢpeptide on invasion and peritoneal metastasis of gastric carcinoma with high peritoneal metastasis potential cell line
Fei-Hu BAI ; Jun WANG ; Juan GAO ; Shuang HAN ; Lin XIA ; Bin JIN ; Huihong ZHAI ; Kaichun WU ; Daiming FAN
Chinese Journal of Digestion 2001;0(12):-
Objective To evaluate the potential utility of PⅢpeptide in anti peritoneum metastasis in gastric carcinoma cells with high peritoneal metastasis potential(GC9811 P).Methods The adhesion and invasion inhibitory effects of PⅢpeptide on GC9811-P cells were detected by in vitro matrix adhe- sion and cell invasion experiments.By using nude mice metastatic model of human gastric cancer,the effects of PⅢpeptide on peritoneal metastasis of gastric cancer GC9811 P were evaluated.Mice were randomly divided into the experimental(GC9811-P+peptide PⅢgroup)and control groups(GC9811-P +0.9% NaCl solution group),12 mice in each group.At the exhaustion time after inoculation,mice were sacrificed to observe the incidence of peritoneal metastasis,the number of the metastasis foci and the volume of primary tumor.Results Two hours after 40?g PⅢpeptide incubation,the adhesion in hibitory rate reached 86.30%.The adhesion inhibitory effects were in a time dependent manner.The in- vasion inhibitory effects became apparent(81.4%)48 hours after PⅢpeptide insult.After the GC9811- P cells were orthotopic implanted in nude mice and treated with PⅢpeptide,the number of peritoneal metastatic nodes were significantly reduced as compared with control group(3.2?6.5 vs.26.3?5.2) ( P<0.01).But the mass of primary tumor were (1.9?1.2) g in PⅢpeptide treated group and (2.1?1.0) g in the control group,no difference was noted between two groups(P>0 05 ).Conclusion PⅢpeptide can markedly inhibit the adhesion,invasion and peritoneal metastasis of gastric carcinoma cell line GC29811-P with high peritoneal metastasis potential
8.Clinical application of molecular adsorbent recirculating system-artificial liver support system.
Xin WANG ; Xinmin ZHOU ; Jiyan MIAO ; Daiming FAN
Chinese Journal of Hepatology 2002;10(3):232-234
Ammonia
;
blood
;
Humans
;
Liver Failure
;
blood
;
pathology
;
therapy
;
Liver, Artificial
;
Urea
;
blood
9.The analysis of prognostic factors in treating variceal hemorrhage of liver cirrhosis and portal hypertension with transjugular intrahepatic portosystemic shunt
Shanshan YUAN ; Guohong HAN ; Ming BAI ; Zhanxin YIN ; Chuangye HE ; Jianhong WANG ; Xingshun QI ; Kaichun WU ; Daiming FAN
Chinese Journal of Digestion 2011;31(5):299-302
Objective To analyze the prognostic factors in treating variceal hemorrhage patients of liver cirrhosis and portal hypertension with transjugular intrahepatic portosystemic shunt (TIPS).Methods From January 2003 to December 2008, the data of 162 variceal hemorrhage patients with liver cirrhosis and portal hypertension treated with TIPS was collected, which included basic information, biochemical examination results within 7 days before the operation, regular follow-up observation after the surgery and survival data. The survival prognostic indexes were assessed with Cox regression model. Results The successful rate of TIPS was 99% (161/162). The median follow up duration was 21 months. Child-Pugh score and blood platelet count (PLT) were closely correlated with survival (P = 0. 003 and 0. 024). The total cumulative survival rate in patients with Child-Pugh score below nine (75%, 102/136) was higher than over nine (50%, 13/26) (χ2 = 9. 12,P=0. 003).The total cumulative survival rate of patients with PLT count over 47 ×109/L (74%, 82/112) was higher than below 47 × 109/L(66 %, 33/50, χ2 =4. 528, P = 0. 033). The one year after operation cumulative survival rate of liver function Child-Pugh class A, B, and C was 92%, 85%, 55% respectively. Conclusion Child-Pugh score and platelet count are independent predictable factors for the survival of variceal hemorrhage patients with liver cirrhosis and portal hypertension treated by TIPS. The risk increase after operation when Child-Pugh score over 9 and/or PLT count less 47×109 /L.
10.Triptolide downregulates Rac1 and the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression.
Zhipeng WANG ; Haifeng JIN ; Ruodan XU ; Qibing MEI ; Daiming FAN
Experimental & Molecular Medicine 2009;41(10):717-727
Triptolide, a diterpenoid triepoxide from the traditional Chinese medicinal herb Tripterygium wilfordii Hook. f., is a potential treatment for autoimmune diseases as well a possible anti-tumor agent. It inhibits proliferation of coloretal cancer cells in vitro and in vivo. In this study, its ability to block progress of colitis to colon cancer, and its molecular mechanism of action are investigated. A mouse model for colitis-induced colorectal cancer was used to test the effect of triptolide on cancer progression. Treatment of mice with triptolide decreased the incidence of colon cancer formation, and increased survival rate. Moreover, triptolide decreased the incidence of tumors in nude mice inoculated with cultured colon cancer cells dose-dependently. In vitro, triptolide inhibited the proliferation, migration and colony formation of colon cancer cells. Secretion of IL6 and levels of JAK1, IL6R and phosphorylated STAT3 were all reduced by triptolide treatment. Triptolide prohibited Rac1 activity and blocked cyclin D1 and CDK4 expression, leading to G1 arrest. Triptolide interrupted the IL6R-JAK/STAT pathway that is crucial for cell proliferation, survival, and inflammation. This suggests that triptolide might be a candidate for prevention of colitis induced colon cancer because it reduces inflammation and prevents tumor formation and development.
Animals
;
Cell Transformation, Neoplastic/*drug effects
;
Colitis/complications
;
Colonic Neoplasms/chemically induced/*drug therapy/metabolism/pathology
;
Dextran Sulfate/toxicity
;
Dimethylhydrazines/toxicity
;
Diterpenes/*administration & dosage
;
Epoxy Compounds/administration & dosage
;
Humans
;
Interleukin-6/biosynthesis
;
Janus Kinases/metabolism
;
Male
;
Mice
;
Mice, Inbred BALB C
;
Mice, Inbred ICR
;
Mice, Nude
;
Neoplasm Transplantation
;
Phenanthrenes/*administration & dosage
;
STAT3 Transcription Factor/metabolism
;
Signal Transduction/*drug effects
;
Tumor Burden/drug effects
;
rac1 GTP-Binding Protein/*biosynthesis